Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia DOI Creative Commons
Gerald F. Watts, David Sullivan, David L. Hare

et al.

Heart Lung and Circulation, Journal Year: 2020, Volume and Issue: 30(3), P. 324 - 349

Published: Dec. 10, 2020

Familial hypercholesterolaemia (FH) is a dominant and highly penetrant monogenic disorder present from birth that markedly elevates plasma low-density lipoprotein (LDL)-cholesterol concentration and, if untreated, leads to premature atherosclerosis coronary artery disease (CAD). There are approximately 100,000 people with FH in Australia. However, an overwhelming majority of those affected remain undetected inadequately treated, consistent being leading challenge for public health genomics. To further address the unmet need, we provide updated guidance, presented as series systematically collated recommendations, on care patients families FH. These recommendations have been informed by exponential growth published works new evidence over last 5 years compatible contemporary global call action Recommendations given detection, diagnosis, assessment management adults children. also made genetic testing risk notification biological relatives who should undergo cascade Guidance based concepts re-stratification, adherence heart healthy lifestyles, treatment non-cholesterol factors, safe appropriate use LDL-cholesterol lowering therapies, including statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors apheresis. Broad provided organisation development services. best practice need be underpinned good clinical judgment shared decision making families. Models adapted local regional needs available resources. A comprehensive realistic implementation strategy, research, assessments cost-benefit, will required ensure this guidance benefits all Australian or at

Language: Английский

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines DOI Open Access
Scott M. Grundy, Neil J. Stone, Alison Bailey

et al.

Circulation, Journal Year: 2019, Volume and Issue: 139(25)

Published: Jan. 17, 2019

Language: Английский

Citations

5468

Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association DOI Creative Commons

Connie W. Tsao,

Aaron W. Aday, Zaid Almarzooq

et al.

Circulation, Journal Year: 2022, Volume and Issue: 145(8)

Published: Jan. 26, 2022

The American Heart Association, in conjunction with the National Institutes of Health, annually reports most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, diet, weight) factors (cholesterol, blood pressure, glucose control) that contribute health. Statistical Update presents latest data on a range major clinical circulatory disease conditions (including congenital rhythm disorders, subclinical atherosclerosis, coronary failure, valvular venous peripheral artery disease) associated outcomes quality care, procedures, economic costs).

Language: Английский

Citations

4265

Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association DOI Creative Commons

Connie W. Tsao,

Aaron W. Aday, Zaid Almarzooq

et al.

Circulation, Journal Year: 2023, Volume and Issue: 147(8)

Published: Jan. 25, 2023

Background: The American Heart Association, in conjunction with the National Institutes of Health, annually reports most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, diet, weight) factors (cholesterol, blood pressure, glucose control) that contribute health. Statistical Update presents latest data on a range major clinical circulatory disease conditions (including congenital rhythm disorders, subclinical atherosclerosis, coronary failure, valvular venous peripheral artery disease) associated outcomes quality care, procedures, economic costs). Methods: through its Epidemiology Prevention Statistics Committee, continuously monitors evaluates sources stroke United States provide current information available annual review published literature year before writing. 2023 is product full year’s worth effort 2022 by dedicated volunteer clinicians scientists, committed government professionals, Association staff members. strives further understand help heal problems inflicted structural racism, public crisis can significantly damage mental perpetuate disparities access education, income, housing, several other vital healthy lives. This edition includes additional COVID-19 (coronavirus 2019) publications, as well monitoring benefits population, an enhanced focus equity across key domains. Results: Each chapters focuses different topic statistics. Conclusions: represents critical resource for lay public, policymakers, media clinicians, care administrators, researchers, advocates, others seeking best these conditions.

Language: Английский

Citations

4232

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol DOI Creative Commons
Scott M. Grundy, Neil J. Stone, Alison Bailey

et al.

Journal of the American College of Cardiology, Journal Year: 2018, Volume and Issue: 73(24), P. e285 - e350

Published: Nov. 10, 2018

Language: Английский

Citations

2101

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary DOI Creative Commons
Scott M. Grundy, Neil J. Stone, Alison Bailey

et al.

Journal of the American College of Cardiology, Journal Year: 2018, Volume and Issue: 73(24), P. 3168 - 3209

Published: Nov. 10, 2018

Language: Английский

Citations

1351

2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association DOI Creative Commons
Seth S. Martin, Aaron W. Aday, Zaid Almarzooq

et al.

Circulation, Journal Year: 2024, Volume and Issue: 149(8)

Published: Jan. 24, 2024

BACKGROUND: The American Heart Association (AHA), in conjunction with the National Institutes of Health, annually reports most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, nutrition, sleep, obesity) factors (cholesterol, blood pressure, glucose control, metabolic syndrome) that contribute health. AHA Disease Stroke Statistical Update presents latest data on a range major clinical circulatory disease conditions (including brain health, complications pregnancy, kidney congenital rhythm disorders, sudden cardiac arrest, subclinical atherosclerosis, coronary cardiomyopathy, failure, valvular venous thromboembolism, peripheral artery disease) associated outcomes quality care, procedures, economic costs). METHODS: AHA, through its Epidemiology Prevention Statistics Committee, continuously monitors evaluates sources stroke United States globally provide current information available annual review published literature year before writing. 2024 is product full year’s worth effort 2023 by dedicated volunteer clinicians scientists, committed government professionals, staff members. strives further understand help heal problems inflicted structural racism, public crisis can significantly damage mental perpetuate disparities access education, income, housing, several other vital healthy lives. This edition includes additional global data, as well monitoring benefits population, an enhanced focus equity across key domains. RESULTS: Each chapters focuses different topic statistics. CONCLUSIONS: represents critical resource for lay public, policymakers, media clinicians, care administrators, researchers, advocates, others seeking best these conditions.

Language: Английский

Citations

914

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines DOI Open Access
Scott M. Grundy, Neil J. Stone, Alison Bailey

et al.

Circulation, Journal Year: 2019, Volume and Issue: 139(25)

Published: Jan. 17, 2019

◼ cardiovascular disease cholesterol, LDL-cholesterol diabetes mellitus drug therapy hydroxymethylglutaryl-CoA reductase inhibitors/statins hypercholesterolemia lipids patient compliance primary prevention risk assessment reduction discussion treatment discussion, secondary ezetimibe proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9) inhibitors

Language: Английский

Citations

693

Clinical Genetic Testing for Familial Hypercholesterolemia DOI Creative Commons
Amy C. Sturm, Joshua W. Knowles, Samuel S. Gidding

et al.

Journal of the American College of Cardiology, Journal Year: 2018, Volume and Issue: 72(6), P. 662 - 680

Published: July 30, 2018

Language: Английский

Citations

490

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association DOI
Don P. Wilson, Terry A. Jacobson,

Peter H. Jones

et al.

Journal of clinical lipidology, Journal Year: 2019, Volume and Issue: 13(3), P. 374 - 392

Published: May 1, 2019

Language: Английский

Citations

428

Familial hypercholesterolaemia DOI
Joep C. Defesche, Samuel S. Gidding, Mariko Harada‐Shiba

et al.

Nature Reviews Disease Primers, Journal Year: 2017, Volume and Issue: 3(1)

Published: Dec. 7, 2017

Language: Английский

Citations

393